

= 100) were evaluated for extrapyramidal side effects (EPS) (blind) as well as other side effects and mental condition (non-blind).

Methods: Chronic schizophrenic patients were evaluated from the charts from the beginning of the present treatment (1–20 years) and prospectively for 5 years. The following rating scales were used: The Sct. Hans Rating Scale for EPS (SHRS) which includes videotape recording, Brief Psychiatric Rating Scale (BPRS), the UKU side effect scale and the Clinical Global Impression scale (CGI).

Results: There was a significantly lower prevalence of tardive dyskinesia (TD) in clozapine treated patients than control patients, although prior to this treatment there were more TD in the clozapine group ($p < 0.05$). This lower level of TD in the clozapine group was related to a lower induction of new cases ($p < 0.001$) and a tendency towards greater disappearance of TD in the clozapine group than in the control group. Clozapine treated patients without TD had started clozapine and ceased traditional neuroleptics at an earlier age than those with TD. Parkinsonian signs were seen in 33% of the clozapine treated patients versus 61% of the control patients. Psychic akathisia was found in 14% versus 40% and motor akathisia in 7% versus 29% of the patients, all differences significantly in favour of clozapine. The 5-year evaluation is going on and will be reported. Preliminary data suggest that the lower induction of new cases of TD and the tendency towards greater disappearance of TD in the clozapine treated group continues resulting in an additional decrease of TD among the clozapine treated patients.

Wed-P60

LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF RISPERIDONE IN ELDERLY PSYCHOTIC PATIENTS

Michael Davidson. *The Risperidone Working Group, Sheba Medical Center, Tel Hashomer, 52621, Israel*

A 12-month, open-label, multicenter trial of risperidone in elderly psychotic patients is being conducted. Results from 106 patients treated for 3 months (endpoint) are reported. The mean daily dose of risperidone (oral solution) at endpoint was 3.7 mg. Statistically significant improvements in psychopathology (score reductions on the Positive and Negative Syndrome Scale and the Clinical Global Impression scale) were shown by the patients at endpoint; 57% were rated as clinically improved ($\geq 20\%$ reduction in PANSS scores). Severity of extrapyramidal symptoms (scores on the Extrapyramidal Symptom Rating Scale) was low at baseline and was significantly reduced during treatment. Thirty-two patients withdrew from the trial, the most common reasons being adverse events (in 14) and insufficient treatment response (in 8). It is concluded that risperidone is effective, well tolerated, and safe in elderly psychotic patients.

Wed-P61

WIE WIRD RISPERIDON IN DER TÄGLICHEN ANWENDUNG DOSIERT: ZWISCHENERGEBNISSE EINER DEUTSCHEN PHASE IV PRÜFUNG

Margot Albus¹*, Christiane A. Klauer, Michael Linden, Michael Philipp. ¹*Bezirkskrankenhaus, Haar, BRD, Germany*

Zur Zeit wird in Deutschland eine Phase IV Prüfung durchgeführt mit dem Ziel, die Langzeitanwendung von Risperidon bei der Behandlung der chronischen Schizophrenie unter Alltagsbedingungen zu untersuchen. Die Patienten werden über einen Zeitraum von 2 Jahren beobachtet, in regelmäßigen Abständen werden das

Vorhandensein psychotischer Symptome, das psychosoziale Funktionsniveau, die Dosierung und Verträglichkeit evaluiert. Diese Zwischenauswertung zeigt die Ergebnisse der ersten 886 Patienten, die im ersten Jahr der Studie eingeschlossen wurden über einen Zeitraum von 6 Monaten. Im Mittel waren die Patienten 12 Jahre krank. Die Minussymptomatik war stärker ausgeprägt als die Plusssymptomatik. Unter der Behandlung mit Risperidon nahmen sowohl psychotische Symptome als auch vorbestehende extrapyramidalmotorische Symptome sowie die Häufigkeit des Gebrauchs von anticholinergischer Medikation ab. Die mittlere Risperidon-Dosis bei Monat 6 war 4.8 ± 1.9 mg pro Tag. Patienten, die mit Neuroleptika vorbehandelt waren, erhielten höhere Risperidon-Dosen als Patienten ohne vorherige neuroleptische Medikation. Im Lauf der Behandlung reduzierte sich die Ko-Medikation mit hochpotenten Neuroleptika, während der Gebrauch von niedrig- und mittelpotenten Neuroleptika als Ko-Medikation im wesentlichen unverändert blieb.

Wed-P62

OVERDOSES WITH 650 MG. OF OLANZAPINE IN A SCHIZOPHRENIC PATIENT

M. Soler-Arrebola¹*, J.J. Lopez Castillo¹, F. Heredia Gil¹, M. Prieto Cuellar¹, M. Soler-Viñolo². ¹*Unit of Psychiatry, Basic General Hospital, Baza, Granada;* ²*Department of Psychiatry, Medical School, University of Granada, Spain*

Olanzapine is an antipsychotic drug that belongs to the tienobenzo-diazepine (group) with affinity for the dopaminergic, serotonergic, adrenergic, histaminergic and muscarinic receptors and a half-life of elimination 30/5 hours. In the present work it's related an intoxication with 650 mg. of Olanzapine (without any other drugs association) in a woman 34 years old, caucasian race, diagnosed of schizophrenia paranoid with 12 years evolution, she was admitted approximately 8 hours after the ingestion of the drug. Before the arrival of the patient to the Hospital, as related by her relatives, she suffered from a confusional syndrome with language disturbance, ataxia, disorientation, excitement with aggressive behaviour and visual hallucinations. The patient was admitted in the I.U.C. with a coma grade IV/V, intermedium pupils with minimal reaction, hyperreflexia, Babinsky (+), temperature 37.8°C; tachycardia 180 p.p.m. that required treatment with amiodarone; hypotension (80/50) that needed continuous perfusion with norepinephrine during the first six hours of her admission; E.C.G. was normal at all moments, having a sinus rhythm, without prolongation of the QT; electrolytic balance which didn't need appropriate diuretic support. In 12 hours time she presented a metabolic acidosis that required bicarbonate perfusion; the agitation episodes decreased with clorazepate 130 mg/day i.v.. After 24 hours she was hemodynamically stable, leaving I.U.C. after 48 hours. During her stay at the Acute Care Unit of Psychiatry neither hematologic and biochemical altered parameters were present, nor persistent somatic (evaluated by U.K.U.) or cognoscitive (Benton visual retention test and Weschler Adult Intelligence Scale) damages related to the intoxication with Olanzapine.

Wed-P63

TREATMENT OF THE SYMPTOMS OF SCHIZOPHRENIA: A META-ANALYSIS COMPARING RISPERIDONE WITH OTHER ANTIPSYCHOTICS

P. Lemmens*, B. Van Baelen, M. Brecher. *Janssen Research Foundation, Turnhoutseweg 30, B-2340 Beerse, Belgium*

Combined data on efficacy were available from 12 double-blind short-term comparative trials of risperidone and other antipsy-